Vaccines based on the cell surface carbohydrates of pathogenic bacteria

Vaccines based on the cell surface carbohydrates of pathogenic bacteria

Glycoconjugate vaccines, in which a cell surface carbohydrate from a micro-organism is covalently attached to an appropriate carrier protein are proving to be the most effective means to generate protective immune responses to prevent a wide range of diseases. The technology appears to be generic and applicable to a wide range of pathogens, as long as antibodies against surface carbohydrates help protect against infection. Three such vaccines, against Haemophilus influenzae type b, Neisseria meningitidis Group C and seven serotypes of Streptococcus pneumoniae, have already been licensed and many others are in development. This article discusses the rationale for the development and use of glycoconjugate vaccines, the mechanisms by which they elicit T cell-dependent immune responses and the implications of this for vaccine development, the role of physicochemical methods in the characterisation and quality control of these vaccines, and the novel products which are under development.

Saved in:
Bibliographic Details
Main Author: Jones,Christopher
Format: Digital revista
Language:English
Published: Academia Brasileira de Ciências 2005
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652005000200009
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0001-37652005000200009
record_format ojs
spelling oai:scielo:S0001-376520050002000092005-05-09Vaccines based on the cell surface carbohydrates of pathogenic bacteriaJones,Christopher Glycoconjugate Vaccines Capsular polysaccharides lipopolysaccharides Glycoconjugate vaccines, in which a cell surface carbohydrate from a micro-organism is covalently attached to an appropriate carrier protein are proving to be the most effective means to generate protective immune responses to prevent a wide range of diseases. The technology appears to be generic and applicable to a wide range of pathogens, as long as antibodies against surface carbohydrates help protect against infection. Three such vaccines, against Haemophilus influenzae type b, Neisseria meningitidis Group C and seven serotypes of Streptococcus pneumoniae, have already been licensed and many others are in development. This article discusses the rationale for the development and use of glycoconjugate vaccines, the mechanisms by which they elicit T cell-dependent immune responses and the implications of this for vaccine development, the role of physicochemical methods in the characterisation and quality control of these vaccines, and the novel products which are under development.info:eu-repo/semantics/openAccessAcademia Brasileira de CiênciasAnais da Academia Brasileira de Ciências v.77 n.2 20052005-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652005000200009en10.1590/S0001-37652005000200009
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Jones,Christopher
spellingShingle Jones,Christopher
Vaccines based on the cell surface carbohydrates of pathogenic bacteria
author_facet Jones,Christopher
author_sort Jones,Christopher
title Vaccines based on the cell surface carbohydrates of pathogenic bacteria
title_short Vaccines based on the cell surface carbohydrates of pathogenic bacteria
title_full Vaccines based on the cell surface carbohydrates of pathogenic bacteria
title_fullStr Vaccines based on the cell surface carbohydrates of pathogenic bacteria
title_full_unstemmed Vaccines based on the cell surface carbohydrates of pathogenic bacteria
title_sort vaccines based on the cell surface carbohydrates of pathogenic bacteria
description Glycoconjugate vaccines, in which a cell surface carbohydrate from a micro-organism is covalently attached to an appropriate carrier protein are proving to be the most effective means to generate protective immune responses to prevent a wide range of diseases. The technology appears to be generic and applicable to a wide range of pathogens, as long as antibodies against surface carbohydrates help protect against infection. Three such vaccines, against Haemophilus influenzae type b, Neisseria meningitidis Group C and seven serotypes of Streptococcus pneumoniae, have already been licensed and many others are in development. This article discusses the rationale for the development and use of glycoconjugate vaccines, the mechanisms by which they elicit T cell-dependent immune responses and the implications of this for vaccine development, the role of physicochemical methods in the characterisation and quality control of these vaccines, and the novel products which are under development.
publisher Academia Brasileira de Ciências
publishDate 2005
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652005000200009
work_keys_str_mv AT joneschristopher vaccinesbasedonthecellsurfacecarbohydratesofpathogenicbacteria
_version_ 1756371854257291264

Similar Items